Community-based treatment of @entity1211 with a low-molecular-weight heparin and XXXX .

@entity1 @entity23294 @entity5 @entity1151 @entity1150 @entity1211 @entity1229
This multicenter, prospective, open label, observational study evaluated practice patterns of physicians using @entity23294 , a low-molecular-weight heparin (LMWH), and @entity1229 for the treatment of @entity1150 ( @entity1150 ) with or without @entity1151 ( @entity1151 ). Short-term recurrence of @entity1211 ( @entity1211 ) and safety were also evaluated. @entity1 with an objective diagnosis of @entity1150 , with or without @entity1151 , were invited by their physician to participate in this study. Treatment was given according to the approved U.S. package inserts for @entity23294 (175 IU/kg SQ QD) and @entity1229 and the clinical judgment of the prescribing physician. Baseline @entity1 history including demographic information and the results of tests to confirm the diagnosis of @entity1150 , with or without @entity1151 , were collected. Follow-up information included the treatment setting in which each dose of @entity23294 was administered, medical training of the @entity1 administering @entity23294 doses, timing of initiation of @entity1229 with respect to that of @entity23294 , length of overlap of @entity23294 and @entity1229 therapy, and adverse experiences. A total of 334 @entity1 were enrolled at 65 sites. @entity1 across a wide age (range 18-93 years old) and body weight (range 40-261 kg) were included. Overall, 27.3% of @entity1 had @entity5 , and 50% of the overall study population reported more than one @entity1211 risk factor. Mean duration of @entity23294 treatment was 7.61 days. Therapy at home was more common in suburban and rural settings than in urban settings. High proportions of @entity1 , even among the small group with concurrent @entity1151 , were treated at home with self-injection. Severity of disease was the primary reason for hospitalization. Home treatment of @entity1150 , with or without @entity1151 , with self administration of @entity23294 at 175 IU SQ once-daily was safe and resulted in an acceptably low rate of recurrent @entity1211 and adverse events. Home therapy in the usual practice setting should achieve substantial overall cost savings in the treatment of @entity1150 .
